The Street Has Finally Recognized The Exelixis Clinical Program Potential
September 22, 2017 at 13:13 PM EDT
Leerink downgraded shares of Exelixis, Inc. (NASDAQ: EXEL) and lowered its price target, citing an $8.6 billion diluted market cap. ...
